JPI-547

Phase 2Small molecule

OOnconic Therapeutics Inc.

JPI-547 is one of 85 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Gastric CancerActive, not recruiting

Pancreatic CancerPhase 1

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Gastric CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

MS Contin

Merck & Co.

Preclinical

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

JPI-547

OOnconic Therapeutics Inc.

Phase 2

1 5

ABI-007

Bristol-Myers Squibb

Preclinical

2 6

Active Comparator

Moderna

Preclinical

1 7

LDE225

Novartis

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 10

Meglitinides

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1/2Not yet recruiting

Gastric Cancer

NCT07364422

Q4 2031

Phase 2Not yet recruiting

Ovarian Cancer

NCT07370818

Clinical

Trials by Indication[1]

Ovarian Cancer2 trials

A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

Active, not recruiting·OOnconic Therapeutics Inc.·Phase 2·NCT05475184·58 enrolled

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

Not yet recruiting·OOnconic Therapeutics Inc.·Phase 2·NCT07370818·81 enrolled

Gastric Cancer1 trial

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

Not yet recruiting·OOnconic Therapeutics Inc.·Phase 1/2·NCT07364422·49 enrolled

Advanced Solid Tumors1 trial

A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

Completed·OOnconic Therapeutics Inc.·Phase 1·NCT04335604·62 enrolled

Pancreatic Cancer1 trial

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Recruiting·OOnconic Therapeutics Inc.·Phase 1·NCT05257993·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for JPI-547. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JPI-547 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JPI-547. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Onconic Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOnconic Therapeutics Inc.

JPI-547

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q4 2031

Trials by Indication[1]

Ovarian Cancer2 trials

Gastric Cancer1 trial

Advanced Solid Tumors1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News